Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer
2018
Tamoxifentreatment for breast cancer may induce
ovarian cystsand supraphysiological levels of serum estrogen. We report successful management with
luteinizing hormone-releasing hormone (LHRH) agonist of
ovarian hyperstimulationinduced by
tamoxifen. A 49-year-old woman was operated on for invasive
ductal carcinomaof the
right breast. She received breast irradiation and adjuvant
tamoxifentherapy. After 2 years, she had a cystic ovarian mass, and her serum concentration of estradiol was 1280 pg/mL. She was treated with an injection of 11.25 mg leuprolide acetate, a long-acting LHRH agonist, without abandoning
tamoxifentherapy. The levels of estradiol decreased to <10 pg/mL and the cystic mass disappeared 2 months later. Three-month depot treatment with LHRH agonists can be useful for patients receiving
tamoxifenfor breast cancer who have
ovarian cystsand supraphysiological levels of estrogen.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
18
References
3
Citations
NaN
KQI